Pay in 4 interest-free payments of $7.09 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
GLP-1 agonists are not FDA-approved for type 1 diabetes (T1D), but research suggests they may help lower A1C and promote weight loss in some people with T1D
That is according to the findings of a study presented on Friday at the European Academy of Neurology congress
The fix: always verify "bacteriostatic" on the water vial label before reconstituting
the study physician attributed the death to pre-existing coronary artery disease unrelated to the drug, but the FDA's Pharmacy Compounding Advisory Committee cited this "unresolved cardiac signal" in December 2024 as a reason to keep the compound off the approved compounding list
Hepatology 50 (5), 13391340 (2009)
After adjusting for differences like age, weight, and health conditions, GLP-1 users were 37 percent more likely to develop alopecia than people taking SGLT-2 inhibitors and 68 percent more likely than those on DPP-4 inhibitors
